Cargando…

The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants

The clinical usefulness of post-diagnosis islet autoantibody levels is unclear and factors that drive autoantibody persistence are poorly defined in type 1 diabetes (T1D). Our aim was to characterise the longitudinal loss of islet autoantibody responses after diagnosis in a large, prospectively samp...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, C L, Fareed, R, Mortimer, G L M, Aitken, R J, Wilson, I V, George, G, Gillespie, K M, Williams, A J K, Long, A E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750828/
https://www.ncbi.nlm.nih.gov/pubmed/36181724
http://dx.doi.org/10.1093/cei/uxac087
_version_ 1784850342908788736
author Williams, C L
Fareed, R
Mortimer, G L M
Aitken, R J
Wilson, I V
George, G
Gillespie, K M
Williams, A J K
Long, A E
author_facet Williams, C L
Fareed, R
Mortimer, G L M
Aitken, R J
Wilson, I V
George, G
Gillespie, K M
Williams, A J K
Long, A E
author_sort Williams, C L
collection PubMed
description The clinical usefulness of post-diagnosis islet autoantibody levels is unclear and factors that drive autoantibody persistence are poorly defined in type 1 diabetes (T1D). Our aim was to characterise the longitudinal loss of islet autoantibody responses after diagnosis in a large, prospectively sampled UK cohort. Participants with T1D [n = 577] providing a diagnosis sample [range −1.0 to 2.0 years] and at least one post-diagnosis sample (<32.0 years) were tested for autoantibodies to glutamate decarboxylase 65 (GADA), islet antigen-2 (IA-2A), and zinc transporter 8 (ZnT8A). Select HLA and non-HLA SNPs were considered. Non-genetic and genetic factors were assessed by multivariable logistic regression models for autoantibody positivity at initial sampling and autoantibody loss at final sampling. For GADA, IA-2A, and ZnT8A, 70.8%, 76.8%, and 40.1%, respectively, remained positive at the final sampling. Non-genetic predictors of autoantibody loss were low baseline autoantibody titres (P < 0.0001), longer diabetes duration (P < 0.0001), and age-at-onset under 8 years (P < 0.01–-0.05). Adjusting for non-genetic covariates, GADA loss was associated with low-risk HLA class II genotypes (P = 0.005), and SNPs associated with autoimmunity RELA/11q13 (P = 0.017), LPP/3q28 (P = 0.004), and negatively with IFIH1/2q24 (P = 0.018). IA-2A loss was not associated with genetic factors independent of other covariates, while ZnT8A loss was associated with the presence of HLA A*24 (P = 0.019) and weakly negatively with RELA/11q13 (P = 0.049). The largest longitudinal study of islet autoantibody responses from diagnosis of T1D shows that autoantibody loss is heterogeneous and influenced by low titres at onset, longer duration, earlier age-at-onset, and genetic variants. These data may inform clinical trials where post-diagnosis participants are recruited.
format Online
Article
Text
id pubmed-9750828
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97508282022-12-16 The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants Williams, C L Fareed, R Mortimer, G L M Aitken, R J Wilson, I V George, G Gillespie, K M Williams, A J K Long, A E Clin Exp Immunol Autoimmunity/Autoimmune disease The clinical usefulness of post-diagnosis islet autoantibody levels is unclear and factors that drive autoantibody persistence are poorly defined in type 1 diabetes (T1D). Our aim was to characterise the longitudinal loss of islet autoantibody responses after diagnosis in a large, prospectively sampled UK cohort. Participants with T1D [n = 577] providing a diagnosis sample [range −1.0 to 2.0 years] and at least one post-diagnosis sample (<32.0 years) were tested for autoantibodies to glutamate decarboxylase 65 (GADA), islet antigen-2 (IA-2A), and zinc transporter 8 (ZnT8A). Select HLA and non-HLA SNPs were considered. Non-genetic and genetic factors were assessed by multivariable logistic regression models for autoantibody positivity at initial sampling and autoantibody loss at final sampling. For GADA, IA-2A, and ZnT8A, 70.8%, 76.8%, and 40.1%, respectively, remained positive at the final sampling. Non-genetic predictors of autoantibody loss were low baseline autoantibody titres (P < 0.0001), longer diabetes duration (P < 0.0001), and age-at-onset under 8 years (P < 0.01–-0.05). Adjusting for non-genetic covariates, GADA loss was associated with low-risk HLA class II genotypes (P = 0.005), and SNPs associated with autoimmunity RELA/11q13 (P = 0.017), LPP/3q28 (P = 0.004), and negatively with IFIH1/2q24 (P = 0.018). IA-2A loss was not associated with genetic factors independent of other covariates, while ZnT8A loss was associated with the presence of HLA A*24 (P = 0.019) and weakly negatively with RELA/11q13 (P = 0.049). The largest longitudinal study of islet autoantibody responses from diagnosis of T1D shows that autoantibody loss is heterogeneous and influenced by low titres at onset, longer duration, earlier age-at-onset, and genetic variants. These data may inform clinical trials where post-diagnosis participants are recruited. Oxford University Press 2022-10-01 /pmc/articles/PMC9750828/ /pubmed/36181724 http://dx.doi.org/10.1093/cei/uxac087 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Autoimmunity/Autoimmune disease
Williams, C L
Fareed, R
Mortimer, G L M
Aitken, R J
Wilson, I V
George, G
Gillespie, K M
Williams, A J K
Long, A E
The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
title The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
title_full The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
title_fullStr The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
title_full_unstemmed The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
title_short The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
title_sort longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
topic Autoimmunity/Autoimmune disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750828/
https://www.ncbi.nlm.nih.gov/pubmed/36181724
http://dx.doi.org/10.1093/cei/uxac087
work_keys_str_mv AT williamscl thelongitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT fareedr thelongitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT mortimerglm thelongitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT aitkenrj thelongitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT wilsoniv thelongitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT georgeg thelongitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT gillespiekm thelongitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT williamsajk thelongitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT thelongitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT longae thelongitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT williamscl longitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT fareedr longitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT mortimerglm longitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT aitkenrj longitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT wilsoniv longitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT georgeg longitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT gillespiekm longitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT williamsajk longitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT longitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants
AT longae longitudinallossofisletautoantibodyresponsesfromdiagnosisoftype1diabetesoccursprogressivelyoverfollowupandisdeterminedbylowautoantibodytitresearlyonsetandgeneticvariants